Highly Selective PTK2 Proteolysis Targeting Chimeras to Probe Focal Adhesion Kinase Scaffolding Functions

Features and development of Coot

Emsley, P., Lohkamp, B., Scott, W. G., & Cowtan, K. D. (2010) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444910007493 · Cited by 27,510 · see citing works

<i>MolProbity</i> : all-atom structure validation for macromolecular crystallography

Chen, V. B., Arendall, W. B., Headd, J. J., Keedy, D. A., Immormino, R. M., Kapral, G. J., Murray, L. W., Richardson, J. S., & Richardson, D. C. (2010) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444909042073 · Cited by 14,115 · see citing works

Hepatocellular Carcinoma

El-Serag, H. B. (2011) · New England Journal of Medicine · doi:10.1056/nejmra1001683 · Cited by 3,529 · see citing works

Protacs: Chimeric molecules that target proteins to the Skp1–Cullin–F box complex for ubiquitination and degradation

Sakamoto, K. M., Kim, K. B., Kumagai, A., Mercurio, F., Crews, C. M., & Deshaies, R. J. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.141230798 · Cited by 2,609 · see citing works

Integration, scaling, space-group assignment and post-refinement

Kabsch, W. (2010) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444909047374 · Cited by 2,494 · see citing works

Function and regulation of cullin–RING ubiquitin ligases

Petroski, M. D., & Deshaies, R. J. (2005) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm1547 · Cited by 2,148 · see citing works

An inhibitor of NEDD8-activating enzyme as a new approach to treat cancer

Soucy, T. A., Smith, P. G., Milhollen, M. A., Berger, A. J., Gavin, J. M., Adhikari, S., Brownell, J. E., Burke, K. E., Cardin, D. P., Critchley, S., et al. (2009) · Nature · doi:10.1038/nature07884 · Cited by 1,990 · see citing works

Computational correction of copy number effect improves specificity of CRISPR-Cas9 essentiality screens in cancer cells

Meyers, R. M., Bryan, J. G., McFarland, J. M., Weir, B. A., Sizemore, A. E., Xu, H., Dharia, N. V., Montgomery, P. G., Cowley, G. S., Pantel, S., et al. (2017) · Nature Genetics · doi:10.1038/ng.3984 · Cited by 1,952 · see citing works

Phthalimide conjugation as a strategy for in vivo target protein degradation

Winter, G. E., Buckley, D. L., Paulk, J., Roberts, J. M., Souza, A., Dhe-Paganon, S., & Bradner, J. E. (2015) · Science · doi:10.1126/science.aab1433 · Cited by 1,760 · see citing works

Induced protein degradation: an emerging drug discovery paradigm

Lai, A. C., & Crews, C. M. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.211 · Cited by 1,486 · see citing works

FAK in cancer: mechanistic findings and clinical applications

Sulzmaier, F. J., Jean, C., & Schlaepfer, D. D. (2014) · Nature Reviews Cancer · doi:10.1038/nrc3792 · Cited by 1,381 · see citing works

Catalytic in vivo protein knockdown by small-molecule PROTACs

Bondeson, D. P., Mares, A., Smith, I. E. D., Ko, E., Campos, S., Miah, A. H., Mulholland, K. E., Routly, N., Buckley, D. L., Gustafson, J. L., et al. (2015) · Nature Chemical Biology · doi:10.1038/nchembio.1858 · Cited by 1,356 · see citing works

Structural basis of PROTAC cooperative recognition for selective protein degradation

Gadd, M. S., Testa, A., Lucas, X., Chan, K.-H., Chen, W., Lamont, D. J., Zengerle, M., & Ciulli, A. (2017) · Nature Chemical Biology · doi:10.1038/nchembio.2329 · Cited by 1,242 · see citing works

Hepatocellular carcinoma: a review

Balogh, J., Victor, D. W., Asham, E. H., Burroughs, S. G., Boktour, M. R., Saharia, A., Li, X., Ghobrial, R. M., & Monsour, H. (2016) · Journal of Hepatocellular Carcinoma · doi:10.2147/jhc.s61146 · Cited by 1,209 · see citing works

Structure of the DDB1–CRBN E3 ubiquitin ligase in complex with thalidomide

Fischer, E. S., Böhm, K., Lydeard, J. R., Yang, H., Stadler, M. B., Cavadini, S., Nagel, J., Serluca, F., Acker, V., Lingaraju, G. M., et al. (2014) · Nature · doi:10.1038/nature13527 · Cited by 1,141 · see citing works

Hijacking the E3 Ubiquitin Ligase Cereblon to Efficiently Target BRD4

Lu, J., Qian, Y., Altieri, M., Dong, H., Wang, J., Raina, K., Hines, J., Winkler, J. D., Crew, A. P., Coleman, K., et al. (2015) · Chemistry &amp; Biology · doi:10.1016/j.chembiol.2015.05.009 · Cited by 1,140 · see citing works

Selective Small Molecule Induced Degradation of the BET Bromodomain Protein BRD4

Zengerle, M., Chan, K.-H., & Ciulli, A. (2015) · ACS Chemical Biology · doi:10.1021/acschembio.5b00216 · Cited by 1,056 · see citing works

Lessons in PROTAC Design from Selective Degradation with a Promiscuous Warhead

Bondeson, D. P., Smith, B. E., Burslem, G. M., Buhimschi, A. D., Hines, J., Jaime-Figueroa, S., Wang, J., Hamman, B. D., Ishchenko, A., & Crews, C. M. (2018) · Cell Chemical Biology · doi:10.1016/j.chembiol.2017.09.010 · Cited by 923 · see citing works

Resection and Liver Transplantation for Hepatocellular Carcinoma

Llovet, J. M., Schwartz, M., & Mazzaferro, V. (2005) · Seminars in Liver Disease · doi:10.1055/s-2005-871198 · Cited by 879 · see citing works

Human P-glycoprotein transports cyclosporin A and FK506.

Saeki, T., Ueda, K., Tanigawara, Y., Hori, R., & Komano, T. (1993) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)53221-x · Cited by 684 · see citing works

Project DRIVE: a compendium of cancer dependencies and synthetic lethal relationships uncovered by large-scale, deep RNAi screening

McDonald, E. R., de Weck, A., Schlabach, M. R., Billy, E., Mavrakis, K. J., Hoffman, G. R., Belur, D., Castelletti, D., Frias, E., Gampa, K., et al. (2017) · Cell · doi:10.1016/j.cell.2017.07.005 · Cited by 658 · see citing works

Modular PROTAC design for the degradation of oncogenic BCR-ABL

Lai, A. C., Toure, M., Hellerschmied, D., Salami, J., Jaime‐Figueroa, S., Ko, E., Hines, J., & Crews, C. M. (2016) · Angewandte Chemie International Edition · doi:10.1002/anie.201507634 · Cited by 618 · see citing works

Plasticity in binding confers selectivity in ligand-induced protein degradation

Nowak, R. P., DeAngelo, S. L., Buckley, D., He, Z., Donovan, K. A., An, J., Safaee, N., Jedrychowski, M. P., Ponthier, C. M., Ishoey, M., et al. (2018) · Nature Chemical Biology · doi:10.1038/s41589-018-0055-y · Cited by 615 · see citing works

Cereblon expression is required for the antimyeloma activity of lenalidomide and pomalidomide

Zhu, Y. X., Braggio, E., Shi, C.-X., Bruins, L. A., Schmidt, J. E., Van Wier, S., Chang, X.-B., Bjorklund, C. C., Fonseca, R., Bergsagel, P. L., et al. (2011) · Blood · doi:10.1182/blood-2011-05-356063 · Cited by 607 · see citing works

A Chemoproteomic Approach to Query the Degradable Kinome Using a Multi-kinase Degrader

Huang, H.-T., Dobrovolsky, D., Paulk, J., Yang, G., Weisberg, E. L., Doctor, Z. M., Buckley, D. L., Cho, J.-H., Ko, E., Jang, J., et al. (2018) · Cell Chemical Biology · doi:10.1016/j.chembiol.2017.10.005 · Cited by 437 · see citing works

Structure-Guided Design and Optimization of Small Molecules Targeting the Protein–Protein Interaction between the von Hippel–Lindau (VHL) E3 Ubiquitin Ligase and the Hypoxia Inducible Factor (HIF) Alpha Subunit with in Vitro Nanomolar Affinities

Galdeano, C., Gadd, M. S., Soares, P., Scaffidi, S., Molle, I. V., Birced, I., Hewitt, S. H., Dias, D. M. G., & Ciulli, A. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm5011258 · Cited by 424 · see citing works

Degradation of the BAF Complex Factor BRD9 by Heterobifunctional Ligands

Remillard, D., Buckley, D. L., Paulk, J., Brien, G. L., Sonnett, M., Seo, H., Dastjerdi, S., Wühr, M., Dhe‐Paganon, S., Armstrong, S. A., et al. (2017) · Angewandte Chemie International Edition · doi:10.1002/anie.201611281 · Cited by 294 · see citing works

Adrenergic modulation of focal adhesion kinase protects human ovarian cancer cells from anoikis

Sood, A. K., Armaiz-Pena, G. N., Halder, J., Nick, A. M., Stone, R. L., Hu, W., Carroll, A. R., Spannuth, W. A., Deavers, M. T., Allen, J. K., et al. (2010) · Journal of Clinical Investigation · doi:10.1172/jci40802 · Cited by 283 · see citing works

Potent and selective chemical probe of hypoxic signalling downstream of HIF-α hydroxylation via VHL inhibition

Frost, J., Galdeano, C., Soares, P., Gadd, M. S., Grzes, K. M., Ellis, L. C. J., Epemolu, O., Shimamura, S., Bantscheff, M., Grandi, P., et al. (2016) · Nature Communications · doi:10.1038/ncomms13312 · Cited by 242 · see citing works

Molecular recognition of ternary complexes: a new dimension in the structure-guided design of chemical degraders

Hughes, S. J., & Ciulli, A. (2017) · Essays in Biochemistry · doi:10.1042/ebc20170041 · Cited by 240 · see citing works

Proteolysis-Targeting Chimeras: Induced Protein Degradation as a Therapeutic Strategy

Ottis, P., & Crews, C. M. (2017) · ACS Chemical Biology · doi:10.1021/acschembio.6b01068 · Cited by 227 · see citing works

Impact of Target Warhead and Linkage Vector on Inducing Protein Degradation: Comparison of Bromodomain and Extra-Terminal (BET) Degraders Derived from Triazolodiazepine (JQ1) and Tetrahydroquinoline (I-BET726) BET Inhibitor Scaffolds

Chan, K.-H., Zengerle, M., Testa, A., & Ciulli, A. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b01912 · Cited by 222 · see citing works

Chemically Induced Degradation of Anaplastic Lymphoma Kinase (ALK)

Powell, C. E., Gao, Y., Tan, L., Donovan, K. A., Nowak, R. P., Loehr, A., Bahcall, M., Fischer, E. S., Jänne, P. A., George, R. E., et al. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b01655 · Cited by 198 · see citing works

Targeting FAK in human cancer: from finding to first clinical trials

Golubovskaya, V. (2014) · Frontiers in bioscience · doi:10.2741/4236 · Cited by 197 · see citing works

FAK overexpression is correlated with tumour invasiveness and lymph node metastasis in oesophageal squamous cell carcinoma

Miyazaki, T., Kato, H., Nakajima, M., Sohda, M., Fukai, Y., Masuda, N., Manda, R., Fukuchi, M., Tsukada, K., & Kuwano, H. (2003) · British Journal of Cancer · doi:10.1038/sj.bjc.6601050 · Cited by 188 · see citing works

Overexpression of focal adhesion kinase, a protein tyrosine kinase, in ovarian carcinoma

Judson, P. L., He, X., Cance, W. G., & Le, L. V. (1999) · Cancer · doi:10.1002/(sici)1097-0142(19991015)86:6 · Cited by 181 · see citing works

Group-Based Optimization of Potent and Cell-Active Inhibitors of the von Hippel–Lindau (VHL) E3 Ubiquitin Ligase: Structure–Activity Relationships Leading to the Chemical Probe (2 S ,4 R )-1-(( S )-2-(1-Cyanocyclopropanecarboxamido)-3,3-dimethylbutanoyl)-4-hydroxy- N -(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide (VH298)

Soares, P., Gadd, M. S., Frost, J., Galdeano, C., Ellis, L. C. J., Epemolu, O., Rocha, S., Read, K. D., & Ciulli, A. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b00675 · Cited by 180 · see citing works

Overexpression of focal adhesion kinase in primary colorectal carcinomas and colorectal liver metastases: immunohistochemistry and real-time PCR analyses.

Lark, A. L., Livasy, C., Calvo, B. F., Caskey, L. S., Moore, D., Yang, X., & Cance, W. G. (2003) · PubMed · Cited by 169 · see citing works

PND-1186 FAK inhibitor selectively promotes tumor cell apoptosis in three-dimensional environments

Tanjoni, I., Walsh, C. T., Uryu, S. A., Tomar, A., Nam, J., Mielgo, A., Lim, S., Liang, C., Koenig, M., Patel, N., et al. (2010) · Cancer Biology & Therapy · doi:10.4161/cbt.9.10.11434 · Cited by 167 · see citing works

Chemical approaches to targeted protein degradation through modulation of the ubiquitin–proteasome pathway

Collins, I., Wang, H., Caldwell, J., & Chopra, R. (2017) · Biochemical Journal · doi:10.1042/bcj20160762 · Cited by 135 · see citing works

Role of Expression of Focal Adhesion Kinase in Progression of Hepatocellular Carcinoma

Itoh, S., Maeda, T., Shimada, M., Aishima, S.-I., Shirabe, K., Tanaka, S., & Maehara, Y. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-1046-03 · Cited by 130 · see citing works

Comparison of Hepatic Resection and Radiofrequency Ablation for Small Hepatocellular Carcinoma: A Meta-Analysis of 16,103 Patients

Xu, Q., Kobayashi, S., Ye, X., & Xia, M. (2014) · Scientific Reports · doi:10.1038/srep07252 · Cited by 111 · see citing works

Inhibition of focal adhesion kinase (FAK) activity prevents anchorage-independent ovarian carcinoma cell growth and tumor progression

Ward, K. K., Tancioni, I., Lawson, C., Miller, N. L. G., Jean, C., Chen, X. L., Uryu, S. A., Kim, J., Tarin, D., Stupack, D. G., et al. (2012) · Clinical & Experimental Metastasis · doi:10.1007/s10585-012-9562-5 · Cited by 109 · see citing works

Focal Adhesion Kinase Versus p53: Apoptosis or Survival?

Cance, W. G., & Golubovskaya, V. (2008) · Science Signaling · doi:10.1126/stke.120pe22 · Cited by 99 · see citing works

Demonstrating In-Cell Target Engagement Using a Pirin Protein Degradation Probe (CCT367766)

Chessum, N. E. A., Sharp, S. Y., Caldwell, J., Pasqua, E., Wilding, B., Colombano, G., Collins, I., Özer, B., Richards, M., Rowlands, M., et al. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b01406 · Cited by 90 · see citing works

The FAK inhibitor BI 853520 exerts anti-tumor effects in breast cancer

Tiede, S., Meyer-Schaller, N., Kalathur, R. K. R., Ivanek, R., Fagiani, E., Schmassmann, P., Stillhard, P., Häfliger, S., Kraut, N., Schweifer, N., et al. (2018) · Oncogenesis · doi:10.1038/s41389-018-0083-1 · Cited by 66 · see citing works

Efficacy of the highly selective focal adhesion kinase inhibitor BI 853520 in adenocarcinoma xenograft models is linked to a mesenchymal tumor phenotype

Hirt, U. A., Waizenegger, I. C., Schweifer, N., Haslinger, C., Gerlach, D., Braunger, J., Weyer-Czernilofsky, U., Stadtmüller, H., Sapountzis, I., Bader, G., et al. (2018) · Oncogenesis · doi:10.1038/s41389-018-0032-z · Cited by 63 · see citing works

Focal adhesion kinase depletion reduces human hepatocellular carcinoma growth by repressing enhancer of zeste homolog 2

Gnani, D., Romito, I., Artuso, S., Chierici, M., Stefanis, C. D., Panera, N., Crudele, A., Ceccarelli, S., Carcarino, E., Doria, V., et al. (2017) · Cell Death and Differentiation · doi:10.1038/cdd.2017.34 · Cited by 60 · see citing works

3′3-Diindolylmethane inhibits migration, invasion and metastasis of hepatocellular carcinoma by suppressing FAK signaling

Li, W., Chen, L., Sun, M., Li, J., Liu, H., & Zhu, W. (2015) · Oncotarget · doi:10.18632/oncotarget.4196 · Cited by 44 · see citing works

Proteolysis-Targeting Chimeras as Therapeutics and Tools for Biological Discovery

Burslem, G. M., & Crews, C. M. (2020) · Cell · doi:10.1016/j.cell.2019.11.031 · Cited by 1,079 · see citing works

Targeted protein degradation: expanding the toolbox

Schapira, M., Calabrese, M. F., Bullock, A. N., & Crews, C. M. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-019-0047-y · Cited by 960 · see citing works

PROTACs: past, present and future

Li, K., & Crews, C. M. (2022) · Chemical Society Reviews · doi:10.1039/d2cs00193d · Cited by 869 · see citing works

PROTACs: great opportunities for academia and industry

Sun, X., Gao, H., Yang, Y., He, M., Wu, Y., Song, Y.-G., Tong, Y., & Rao, Y. (2019) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-019-0101-6 · Cited by 651 · see citing works

PROTACs: An Emerging Therapeutic Modality in Precision Medicine

Nalawansha, D. A., & Crews, C. M. (2020) · Cell chemical biology · doi:10.1016/j.chembiol.2020.07.020 · Cited by 514 · see citing works

Targeting FAK in anticancer combination therapies

Dawson, J. C., Serrels, A., Stupack, D. G., Schlaepfer, D. D., & Frame, M. C. (2021) · Nature reviews. Cancer · doi:10.1038/s41568-021-00340-6 · Cited by 397 · see citing works

Proteolysis-targeting chimeras (PROTACs) in cancer therapy

Li, X., Pu, W., Zheng, Q., Ai, M., Chen, S., & Peng, Y. (2022) · Molecular Cancer · doi:10.1186/s12943-021-01434-3 · Cited by 374 · see citing works

PROTAC Technology: Opportunities and Challenges

Gao, H., Sun, X., & Rao, Y. (2020) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.9b00597 · Cited by 361 · see citing works

The PROTACtable genome

Schneider, M., Radoux, C. J., Hercules, A., Ochoa, D., Dunham, I., Zalmas, L.-P., Hessler, G., Ruf, S., Shanmugasundaram, V., Hann, M. M., et al. (2021) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00245-x · Cited by 273 · see citing works

Proteolysis targeting chimera (PROTAC) in drug discovery paradigm: Recent progress and future challenges

Zeng, S., Huang, W., Zheng, X., Cheng, L., Zhang, Z., Wang, J., & Shen, Z. (2020) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2020.112981 · Cited by 262 · see citing works

Discovery of small molecule ligands for the von Hippel-Lindau (VHL) E3 ligase and their use as inhibitors and PROTAC degraders

Diehl, C. J., & Ciulli, A. (2022) · Chemical Society Reviews · doi:10.1039/d2cs00387b · Cited by 259 · see citing works

Trivalent PROTACs enhance protein degradation via combined avidity and cooperativity

Imaide, S., Riching, K. M., Makukhin, N., Vetma, V., Whitworth, C., Hughes, S. J., Trainor, N., Mahan, S. D., Murphy, N., Cowan, A. D., et al. (2021) · Nature Chemical Biology · doi:10.1038/s41589-021-00878-4 · Cited by 251 · see citing works

Discovery of XL01126: A Potent, Fast, Cooperative, Selective, Orally Bioavailable, and Blood–Brain Barrier Penetrant PROTAC Degrader of Leucine-Rich Repeat Kinase 2

Liu, X., Kalogeropulou, A. F., Domingos, S., Makukhin, N., Nirujogi, R. S., Singh, F., Shpiro, N., Saalfrank, A., Sammler, E. M., Ganley, I. G., et al. (2022) · Journal of the American Chemical Society · doi:10.1021/jacs.2c05499 · Cited by 198 · see citing works

Harnessing the Power of Proteolysis for Targeted Protein Inactivation

Verma, R., Mohl, D., & Deshaies, R. J. (2020) · Molecular Cell · doi:10.1016/j.molcel.2020.01.010 · Cited by 185 · see citing works

E3 ligase ligand chemistries: from building blocks to protein degraders

Sosič, I., Bricelj, A., & Steinebach, C. (2022) · Chemical Society Reviews · doi:10.1039/d2cs00148a · Cited by 173 · see citing works

Antibody-Mediated Delivery of Chimeric BRD4 Degraders. Part 2: Improvement of In Vitro Antiproliferation Activity and In Vivo Antitumor Efficacy

Dragovich, P. S., Pillow, T. H., Blake, R. A., Sadowsky, J. D., Adaligil, E., Adhikari, P., Chen, J., Corr, N., dela Cruz-Chuh, J., Del Rosario, G., et al. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c01846 · Cited by 174 · see citing works

Fundamental aspects of DMPK optimization of targeted protein degraders

Cantrill, C., Chaturvedi, P., Rynn, C., Schaffland, J. P., Walter, I., & Wittwer, M. (2020) · Drug Discovery Today · doi:10.1016/j.drudis.2020.03.012 · Cited by 169 · see citing works

Revisiting the grammar of Tau aggregation and pathology formation: how new insights from brain pathology are shaping how we study and target Tauopathies

Limorenko, G., & Lashuel, H. A. (2021) · Chemical Society Reviews · doi:10.1039/d1cs00127b · Cited by 162 · see citing works

Developing degraders: principles and perspectives on design and chemical space

Maple, H. J., Clayden, N., Baron, A., Stacey, C., & Felix, R. L. (2019) · MedChemComm · doi:10.1039/c9md00272c · Cited by 159 · see citing works

The role of reversible and irreversible covalent chemistry in targeted protein degradation

Kiely‐Collins, H., Winter, G. E., & Bernardes, G. J. L. (2021) · Cell chemical biology · doi:10.1016/j.chembiol.2021.03.005 · Cited by 156 · see citing works

Developments of CRBN-based PROTACs as potential therapeutic agents

Wang, C., Zhang, Y., Wu, Y., & Xing, D. (2021) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2021.113749 · Cited by 152 · see citing works

Antibody-Mediated Delivery of Chimeric BRD4 Degraders. Part 1: Exploration of Antibody Linker, Payload Loading, and Payload Molecular Properties

Dragovich, P. S., Pillow, T. H., Blake, R. A., Sadowsky, J. D., Adaligil, E., Adhikari, P., Bhakta, S., Blaquiere, N., Chen, J., dela Cruz-Chuh, J., et al. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c01845 · Cited by 152 · see citing works

Driving E3 Ligase Substrate Specificity for Targeted Protein Degradation: Lessons from Nature and the Laboratory

Cowan, A. D., & Ciulli, A. (2022) · Annual Review of Biochemistry · doi:10.1146/annurev-biochem-032620-104421 · Cited by 129 · see citing works

Discovery and Characterisation of Highly Cooperative FAK‐Degrading PROTACs

Law, R. P., Nunes, J., Chung, C., Bantscheff, M., Buda, K., Dai, H., Evans, J. P., Flinders, A., Klimaszewska, D., Lewis, A. J., et al. (2021) · Angewandte Chemie International Edition · doi:10.1002/anie.202109237 · Cited by 121 · see citing works

PROTAC’ing oncoproteins: targeted protein degradation for cancer therapy

Kelm, J. M., Pandey, D. S., Malin, E., Kansou, H. W., Arora, S., Kumar, R., & Gavande, N. S. (2023) · Molecular Cancer · doi:10.1186/s12943-022-01707-5 · Cited by 115 · see citing works

Progress in the Development of Small Molecular Inhibitors of Focal Adhesion Kinase (FAK)

Lu, Y., & Sun, H. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c01248 · Cited by 104 · see citing works

Mechanistic and Structural Features of PROTAC Ternary Complexes

Casement, R., Bond, A. G., Craigon, C., & Ciulli, A. (2021) · Methods in molecular biology · doi:10.1007/978-1-0716-1665-9_5 · Cited by 105 · see citing works

Designing Soluble PROTACs: Strategies and Preliminary Guidelines

Jiménez, D. G., Sebastiano, M. R., Vallaro, M., Mileo, V., Pizzirani, D., Moretti, E., Ermondi, G., & Caron, G. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.2c00201 · Cited by 103 · see citing works

Target protein localization and its impact on PROTAC-mediated degradation

Simpson, L. M., Glennie, L., Brewer, A., Zhao, J., Crooks, J., Shpiro, N., & Sapkota, G. P. (2022) · Cell chemical biology · doi:10.1016/j.chembiol.2022.08.004 · Cited by 100 · see citing works

Design and Characterization of SGK3-PROTAC1, an Isoform Specific SGK3 Kinase PROTAC Degrader

Tovell, H., Testa, A., Zhou, H., Shpiro, N., Crafter, C., Ciulli, A., & Alessi, D. R. (2019) · ACS Chemical Biology · doi:10.1021/acschembio.9b00505 · Cited by 95 · see citing works

Current advances and development strategies of orally bioavailable PROTACs

Zeng, S., Ye, Y., Xia, H., Min, J., Xu, J., Wang, Z., Pan, Y., Zhou, X., & Huang, W. (2023) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2023.115793 · Cited by 89 · see citing works

Roles and inhibitors of FAK in cancer: current advances and future directions

Hu, H.-H., Wang, S., Shang, H.-L., Lv, H., Chen, B., Gao, S., & Chen, X. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1274209 · Cited by 91 · see citing works

Design, Synthesis, and Evaluation of Highly Potent FAK-Targeting PROTACs

Gao, H., Wu, Y., Sun, Y., Yang, Y., Zhou, G., & Rao, Y. (2019) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.9b00372 · Cited by 87 · see citing works

Proteolysis targeting chimeras (PROTACs) in cancer therapy

Ocaña, A., & Pandiella, A. (2020) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-020-01672-1 · Cited by 87 · see citing works

Drug Discovery Targeting Focal Adhesion Kinase (FAK) as a Promising Cancer Therapy

Pang, X., Liu, X., Liu, Y., Liu, W., Li, Y.-R., Yu, G.-X., Tian, X., Zhang, Y., Song, J., Jin, C., et al. (2021) · Molecules · doi:10.3390/molecules26144250 · Cited by 85 · see citing works

VHL-based PROTACs as potential therapeutic agents: Recent progress and perspectives

Wang, C., Zhang, Y., Wang, J., & Xing, D. (2021) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2021.113906 · Cited by 71 · see citing works

Transforming targeted cancer therapy with PROTACs: A forward-looking perspective

Farnaby, W., Koegl, M., McConnell, D. B., & Ciulli, A. (2021) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2021.02.009 · Cited by 65 · see citing works

Discovery of a Potent Degrader for Fibroblast Growth Factor Receptor 1/2

Du, G., Jiang, J., Wu, Q., Henning, N. J., Donovan, K. A., Yue, H., Che, J., Lu, W., Fischer, E. S., Bardeesy, N. M., et al. (2021) · Angewandte Chemie International Edition · doi:10.1002/anie.202101328 · Cited by 66 · see citing works

Targeted protein degradation in cancers: Orthodox PROTACs and beyond

Li, J., Chen, X., Lü, A., & Liang, C. (2023) · The Innovation · doi:10.1016/j.xinn.2023.100413 · Cited by 66 · see citing works

Ubiquitin-specific proximity labeling for the identification of E3 ligase substrates

Huang, H., Lumpkin, R. J., Tsai, R. W., Su, S., Zhao, X., Xiong, Y., Chen, J., Mageed, N., Donovan, K. A., Fischer, E. S., et al. (2024) · Nature Chemical Biology · doi:10.1038/s41589-024-01590-9 · Cited by 64 · see citing works

Proteolysis Targeting Chimera (PROTAC) for Macrophage Migration Inhibitory Factor (MIF) Has Anti‐Proliferative Activity in Lung Cancer Cells

Xiao, Z., Song, S., Chen, D., van Merkerk, R., van der Wouden, P. E., Cool, R. H., Quax, W. J., Poelarends, G. J., Melgert, B. N., & Dekker, F. J. (2021) · Angewandte Chemie International Edition · doi:10.1002/anie.202101864 · Cited by 63 · see citing works

Opportunities and Challenges of Small Molecule Induced Targeted Protein Degradation

He, M., Lv, W., & Rao, Y. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.685106 · Cited by 62 · see citing works

The Development of FAK Inhibitors: A Five-Year Update

Spallarossa, A., Tasso, B., Russo, E., Villa, C., & Brullo, C. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23126381 · Cited by 58 · see citing works

Targeting Protein Kinases Degradation by PROTACs

Yu, F., Cai, M., Shao, L., & Zhang, J. (2021) · Frontiers in Chemistry · doi:10.3389/fchem.2021.679120 · Cited by 54 · see citing works

Targeting focal adhesion kinase (FAK) for cancer therapy: FAK inhibitors, FAK-based dual-target inhibitors and PROTAC degraders

Yang, M. J., Xiang, H., & Luo, G. (2024) · Biochemical Pharmacology · doi:10.1016/j.bcp.2024.116246 · Cited by 56 · see citing works

Targeting the Non-Catalytic Functions: a New Paradigm for Kinase Drug Discovery?

Wang, Z., Huang, W., Zhou, K., Ren, X., & Ding, K. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c01978 · Cited by 52 · see citing works

Aminopyrimidines: Recent synthetic procedures and anticancer activities

Filho, É. V., Pinheiro, E. M. C., Pinheiro, S., & Greco, S. J. (2021) · Tetrahedron · doi:10.1016/j.tet.2021.132256 · Cited by 48 · see citing works

Focal adhesion kinase signaling – tumor vulnerabilities and clinical opportunities

Schlaepfer, D. D., Ojalill, M., & Stupack, D. G. (2024) · Journal of Cell Science · doi:10.1242/jcs.261723 · Cited by 51 · see citing works

Target Validation Using PROTACs: Applying the Four Pillars Framework

Nowak, R. P., & Jones, L. H. (2020) · SLAS DISCOVERY · doi:10.1177/2472555220979584 · Cited by 48 · see citing works

Selectivity through Targeted Protein Degradation (TPD)

Gopalsamy, A. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.2c00397 · Cited by 46 · see citing works

Degraders early developability assessment: face-to-face with molecular properties

Ermondi, G., Vallaro, M., & Caron, G. (2020) · Drug Discovery Today · doi:10.1016/j.drudis.2020.06.015 · Cited by 40 · see citing works

Discovery of a Brigatinib Degrader SIAIS164018 with Destroying Metastasis-Related Oncoproteins and a Reshuffling Kinome Profile

Ren, C., Sun, N., Liu, H., Kong, Y., Sun, R., Qiu, X., Chen, J., Li, Y., Zhang, J., Zhou, Y., et al. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c00373 · Cited by 41 · see citing works

PROTACs, molecular glues and bifunctionals from bench to bedside: Unlocking the clinical potential of catalytic drugs

Maneiro, M., Vita, E. D., Conole, D., Kounde, C. S., Zhang, Q., & Tate, E. W. (2021) · Progress in medicinal chemistry · doi:10.1016/bs.pmch.2021.01.002 · Cited by 38 · see citing works

Molecular Docking, Molecular Dynamics Simulations, and Free Energy Calculation Insights into the Binding Mechanism between VS-4718 and Focal Adhesion Kinase

Shi, M., Chen, T., Wei, S., Zhao, C., Zhang, X., Li, X., Tang, X., Liu, Y., Yang, Z., & Chen, L. (2022) · ACS Omega · doi:10.1021/acsomega.2c03951 · Cited by 36 · see citing works

Scaffold hopping enables direct access to more potent PROTACs with in vivo activity

Burslem, G. M., Bondeson, D. P., & Crews, C. M. (2020) · Chemical Communications · doi:10.1039/d0cc02201b · Cited by 35 · see citing works

Heterocyclic Compounds as Synthetic Tyrosinase Inhibitors: Recent Advances

Vittorio, S., Dank, C., & Ielo, L. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24109097 · Cited by 35 · see citing works

Tubulin Resists Degradation by Cereblon-Recruiting PROTACs

Gasic, I., Groendyke, B. J., Nowak, R. P., Yuan, J., Kalabathula, J., Fischer, E. S., Gray, N. S., & Mitchison, T. J. (2020) · Cells · doi:10.3390/cells9051083 · Cited by 34 · see citing works

Targeting focal adhesion kinase (FAK) in cancer therapy: A recent update on inhibitors and PROTAC degraders

Wang, X., Li, N., Liu, Y., Wu, J., Liu, Q.-G., Niu, J.-B., Xu, Y., Huang, C., Zhang, S., & Song, J. (2024) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2024.116678 · Cited by 33 · see citing works

FAK-targeting PROTAC demonstrates enhanced antitumor activity against KRAS mutant non-small cell lung cancer

Liu, J., Xue, L., Xu, X., Luo, J., & Zhang, S. (2021) · Experimental Cell Research · doi:10.1016/j.yexcr.2021.112868 · Cited by 33 · see citing works

Identification of novel and potent PROTACs targeting FAK for non-small cell lung cancer: Design, synthesis, and biological study

Sun, Y., Wang, R., Sun, Y., Wang, L., Xue, Y., Wang, J., Wu, T., Yin, W., Qin, Q., Sun, Y., et al. (2022) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2022.114373 · Cited by 33 · see citing works

The efflux pump ABCC1/MRP1 constitutively restricts PROTAC sensitivity in cancer cells

Wolf, G., Craigon, C., Teoh, S. T., Essletzbichler, P., Onstein, S., Cassidy, D. M., Uijttewaal, E. C. H., Dvorak, V., Cao, Y., Bensimon, A., et al. (2025) · Cell chemical biology · doi:10.1016/j.chembiol.2024.11.009 · Cited by 31 · see citing works

Progress of small molecules for targeted protein degradation: PROTACs and other technologies

Zhao, H., Xin, M., & Zhang, S. (2023) · Drug Development Research · doi:10.1002/ddr.22026 · Cited by 31 · see citing works

Protacs in cancer therapy: mechanisms, design, clinical trials, and future directions

Vikal, A., Maurya, R., Patel, B. B., Sharma, R. K., Patel, P., Patil, U. K., & Kurmi, B. D. (2024) · Drug Delivery and Translational Research · doi:10.1007/s13346-024-01754-z · Cited by 28 · see citing works

Small-molecule-based targeted therapy in liver cancer

Ming, Y., Gong, Y., Fu, X., Ouyang, X., Peng, Y., & Pu, W. (2024) · Molecular Therapy · doi:10.1016/j.ymthe.2024.08.001 · Cited by 27 · see citing works

Emerging modes-of-action in drug discovery

Valeur, E., Narjes, F., Ottmann, C., & Plowright, A. T. (2019) · MedChemComm · doi:10.1039/c9md00263d · Cited by 27 · see citing works

Elucidation of genome-wide understudied proteins targeted by PROTAC-induced degradation using interpretable machine learning

Xie, L., & Xie, L. (2023) · PLOS Computational Biology · doi:10.1371/journal.pcbi.1010974 · Cited by 26 · see citing works

Design, synthesis and biological evaluation of 7-((7H-pyrrolo[2,3-d]pyrimidin-4-yl)oxy)-2,3-dihydro-1H-inden-1-one derivatives as potent FAK inhibitors for the treatment of ovarian cancer

Wei, W., Feng, Z., Liu, Z., Li, X., He, H., Ran, K., Shi, Y., Zhu, Y., Ye, T., Gao, C., et al. (2021) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2021.113978 · Cited by 27 · see citing works

Design, synthesis, and biological evaluation of potent FAK-degrading PROTACs

Qin, Q., Wang, R., Fu, Q., Zhang, G., Wu, T., Liu, N., Lv, R., Yin, W., Sun, Y., Sun, Y., et al. (2022) · Journal of Enzyme Inhibition and Medicinal Chemistry · doi:10.1080/14756366.2022.2100886 · Cited by 24 · see citing works

Development of novel focal adhesion kinase (FAK) inhibitors for targeting cancer: Structural insights and therapeutic potential

Li, Y., Zhang, Y., Zhang, J., Zhan, Z., & Mao, W. (2024) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2024.116913 · Cited by 22 · see citing works

MiR-520d-5p functions as a tumor-suppressor gene in cervical cancer through targeting PTK2

Zhang, L., Liu, F., Fu, Y., Chen, X., & Zhang, D. (2020) · Life Sciences · doi:10.1016/j.lfs.2020.117558 · Cited by 21 · see citing works

Application of PROTACs in target identification and validation

Liu, Y., Liang, J. Y., Zhu, R., Yang, Y., Wang, Y., Wei, W., Li, H., & Chen, L. (2024) · Acta Materia Medica · doi:10.15212/amm-2024-0010 · Cited by 20 · see citing works

Design, synthesis, and biological evaluation of novel covalent inhibitors targeting focal adhesion kinase

Chen, T., Liu, Y., Shi, M., Tang, M., Si, W., Yuan, X., Wen, Y., & Chen, L. (2021) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2021.128433 · Cited by 20 · see citing works

Identification of PDE6D as a potential target of sorafenib via PROTAC technologyPreprint

Li, Y., Meng, Q., Wang, P., Liu, X., Fu, Q., Xie, Y., Zhou, Y., Qi, X., & Huang, N. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.05.06.079947 · Cited by 20 · see citing works

FAK Inhibitors As Promising Anticancer Targets: Present and Future Directions

Mustafa, M., El‐Hafeez, A. A. A., Abdelhafeez, D. A., Abdelhamid, D. S., Mostafa, Y. A., Ghosh, P., Hayallah, A. M., & Abuo‐Rahma, G. E. A. (2021) · Future Medicinal Chemistry · doi:10.4155/fmc-2021-0015 · Cited by 17 · see citing works

Proteolysis-targeting chimeras: A promising technique in cancer therapy for gaining insights into tumor development

Lv, M., Hu, W., Zhang, S., He, L., Hu, C., & Yang, S. (2022) · Cancer Letters · doi:10.1016/j.canlet.2022.215716 · Cited by 19 · see citing works

Ternary Complex Modeling, Induced Fit Docking and Molecular Dynamics Simulations as a Successful Approach for the Design of VHL‐Mediated PROTACs Targeting the Kinase FLT3

Nassar, H., Sarnow, A., Celik, I., Abdelsalam, M. A. M., Robaa, D., & Sippl, W. (2025) · Archiv der Pharmazie · doi:10.1002/ardp.202500102 · Cited by 17 · see citing works

Narciclasine suppresses esophageal cancer cell proliferation and migration by inhibiting the FAK signaling pathway

Qiu, Y., Fang, B., Thủy, N. T. T., Li, A., Yoo, H. M., Zheng, X., & Cho, N. (2022) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2021.174669 · Cited by 18 · see citing works

A comprehensive mechanistic investigation of factors affecting intestinal absorption and bioavailability of two PROTACs in rats

Niessen, J., Arendt, N., Sjöblom, M., Dubbelboer, I. R., Borchardt, T. B., Koziolek, M., Hedeland, M., Lennernäs, H., Indulkar, A. S., & Dahlgren, D. (2025) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2025.114719 · Cited by 17 · see citing works

Design, synthesis and biological evaluation of novel FAK inhibitors with better selectivity over IR than TAE226

Chen, T., Liu, Y., Liu, J., Tang, M., Huang, H., Bai, C., Si, W., Yang, T., Yuan, X., Wen, Y., et al. (2022) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2022.105790 · Cited by 17 · see citing works

Development and Characterization of Selective FAK Inhibitors and PROTACs with In Vivo Activity

Koide, E., Mohardt, M. L., Doctor, Z. M., Yang, A., Hao, M., Donovan, K. A., Kuismi, C. C., Nelson, A. J., Abell, K., Aguiar, M., et al. (2023) · ChemBioChem · doi:10.1002/cbic.202300141 · Cited by 18 · see citing works

Design and pharmaceutical applications of proteolysis-targeting chimeric molecules

Liang, Y., Nandakumar, K. S., & Cheng, K. (2020) · Biochemical Pharmacology · doi:10.1016/j.bcp.2020.114211 · Cited by 16 · see citing works

Photoactive Bifunctional Degraders: Precision Tools To Regulate Protein Stability

Kounde, C. S., & Tate, E. W. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c01542 · Cited by 17 · see citing works

Protein kinases: The key contributors in pathogenesis and treatment of nonalcoholic fatty liver disease-derived hepatocellular carcinoma

Liu, R., Qian, M., & Cui, Y. (2023) · Metabolism · doi:10.1016/j.metabol.2023.155665 · Cited by 16 · see citing works

A novel FAK-degrading PROTAC molecule exhibited both anti-tumor activities and efficient MDR reversal effects

Xu, M.-S., Gu, X.-F., Li, C., Pan, L., Zhu, Z., Fan, M., Zhao, Y., Chen, J., Liu, X., & Zhang, X. (2024) · Acta Pharmacologica Sinica · doi:10.1038/s41401-024-01312-w · Cited by 16 · see citing works

Degraders: The Ultimate Weapon Against Amplified Driver Kinases in Cancer

Torres‐Ayuso, P., & Brognard, J. (2022) · Molecular Pharmacology · doi:10.1124/molpharm.121.000306 · Cited by 15 · see citing works

Computational investigation of novel pyrimidine derivatives as potent FAK inhibitors via 3D-QSAR, molecular docking, molecular dynamics simulation and retrosynthesis

Bahi, S. E., Boutalaka, M., Alaouy, M. A. E., Bouamrane, S., Alaqarbeh, M., Choukrad, M., Sbai, A., Bouachrıne, M., & Lakhlifi, T. (2023) · New Journal of Chemistry · doi:10.1039/d3nj02471g · Cited by 14 · see citing works

Razing the scaffolding: the elimination of non-catalytic functions of kinases through targeted protein degradation

Pogash, S., & Fletcher, S. (2025) · RSC Medicinal Chemistry · doi:10.1039/d5md00095e · Cited by 13 · see citing works

Development of the nonreceptor tyrosine kinase FER-targeting PROTACs as a potential strategy for antagonizing ovarian cancer cell motility and invasiveness

Zhang, Y., Xiong, X., Sun, R., Zhu, X., Wang, C., Jiang, B., Yang, X., Li, D., & Fan, G. (2023) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2023.104825 · Cited by 13 · see citing works

Recent Advances in the Design and Development of Anticancer Molecules based on PROTAC Technology

Mukhamejanova, Z., Tong, Y., Xiang, Q., Xu, F., & Pang, J. (2020) · Current Medicinal Chemistry · doi:10.2174/0929867327666200312112412 · Cited by 13 · see citing works

Combinatorial Ubiquitination REal-time PROteolysis (CURE-PROs): A Modular Platform for Generating Reversible, Self-Assembling Bifunctional Targeted Degraders

Giardina, S. F., Valdambrini, E., Singh, P. K., Bacolod, M. D., Babu-Karunakaran, G., Peel, M. R., Warren, J. D., & Barany, F. (2024) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.3c02097 · Cited by 12 · see citing works

Advancing target validation with PROTAC technology

Spitz, M. L., Kashkush, A., & Benhamou, R. I. (2025) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2025.2490248 · Cited by 12 · see citing works

Pharmacodynamic Models of Indirect Effects and Irreversible Inactivation with Turnover: Applicability to Mechanism-Based Modeling of Gene Silencing and Targeted Protein Degradation

Wang, A. F., & Ayyar, V. S. (2023) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2023.10.027 · Cited by 10 · see citing works

Focal adhesion kinase inhibitors in fibrotic diseases therapy: Development and therapeutic potential.

Gan, C.-L., Wei, W., Xue, T.-X., Xie, Y.-T., Yue, L., Su, X.-P., Yu, Y., Liu, Z.-H., & Ye, T.-H. (2025) · European journal of medicinal chemistry · doi:10.1016/j.ejmech.2025.117882 · Cited by 10 · see citing works

Recent advances in focal adhesion kinase (FAK)-targeting antitumor agents

Zhu, S.-K., Wu, Q., Liu, G., Geng, A., & Wang, P. (2025) · RSC Advances · doi:10.1039/d5ra01880c · Cited by 10 · see citing works

Dégradation induite des protéines par des molécules PROTAC et stratégies apparentées : développements à visée thérapeutique

Reboud‐Ravaux, M. (2021) · Biologie Aujourd hui · doi:10.1051/jbio/2021007 · Cited by 9 · see citing works

PROTAC Degraders

Ciulli, A., & Hsia, O. (2022) · doi:10.1002/9781119774198.ch9 · Cited by 8 · see citing works

Discovery of a Potent Degrader for Fibroblast Growth Factor Receptor 1/2

Du, G., Jiang, J., Wu, Q., Henning, N. J., Donovan, K. A., Yue, H., Che, J., Lu, W., Fischer, E. S., Bardeesy, N. M., et al. (2021) · Angewandte Chemie · doi:10.1002/ange.202101328 · Cited by 7 · see citing works

From Degraders to Molecular Glues: New Ways of Breaking Down Disease‐Associated Proteins

Nagel, Y. A., Britschgi, A., & Ricci, A. (2021) · Wiley eBooks · doi:10.1002/9783527826872.ch2 · Cited by 6 · see citing works

Targeting focal adhesion kinase: from molecular mechanisms to next-generation cancer therapeutics

Chen, J., Bu, Z., & Zhan, Q. (2026) · 中国科学通报：英文版 · doi:10.1016/j.scib.2026.02.048 · Cited by 6 · see citing works

PROTAC-mediated Target Degradation: A Paradigm Changer in Drug Discovery?

Cromm, P. M., Crews, C. M., & Weinmann, H. (2020) · Royal Society of Chemistry eBooks · doi:10.1039/9781839160691-00001 · Cited by 6 · see citing works

Chemically induced degradation of CK2 by proteolysis targeting chimeras based on a ubiquitin-proteasome pathway

Chen, H., Chen, F., Liu, N., Wang, X., & Gou, S. (2018) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2018.09.005 · Cited by 51 · see citing works

Novel Proteolysis Targeting Chimeras for the targeted degradation of the protein kinase CK2

Day-Riley, S. (2025) · Apollo (University of Cambridge) · doi:10.17863/cam.127649

Abstract 409: Targeted degradation of FAK and PYK2 in cancer

Kuismi, C. C., Jiang, Y., Jiang, B., & Nabet, B. (2025) · Cancer Research · doi:10.1158/1538-7445.am2025-409

Identification and Characterization of Von Hippel-Lindau-Recruiting Proteolysis Targeting Chimeras (PROTACs) of TANK-Binding Kinase 1

Crew, A. P., Raina, K., Dong, H., Qian, Y., Wang, J., Vigil, D., Serebrenik, Y. V., Hamman, B. D., Morgan, A., Ferraro, C., et al. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b00635 · Cited by 257 · see citing works

Discovery of PVD-06 as a Subtype-Selective and Efficient PTPN2 Degrader

Hu, L., Li, H., Qin, J., Yang, D., Liu, J., Luo, X., Ma, J., Luo, C., Ye, F., Zhou, Y., et al. (2023) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.3c01348 · Cited by 20 · see citing works